Filing history

Suzhou Ailong Technology— every filing summary in full, newest first. The status card's three-section read is synthesized from exactly these.

Synthesized read · Sep 28, 2026

Where it stands688329.SH (Suzhou Ailong Technology, STAR Market) is a profitable but thinly-margined automation equipment maker — not a pre-revenue pharma name and not a radiation-therapy company — so the Pharma cash-runway rule and the RadTech book-to-bill rule are out of scope on this fact set. The balance sheet is the story: TTM EBITDA of CNY 16.7m against net debt of CNY 61.2m (gross debt CNY 184.2m less cash CNY 123.0m) puts net leverage at ~3.66x, above the 2.5x flag line and past the 3.5x escalation trigger; on a gross basis, debt is ~11.0x EBITDA. Margins are thin: a 49.2% gross margin collapses to 3.8% EBITDA margin and 4.5% net margin, implying roughly CNY 201m of operating expense against CNY 442m of revenue. Offsets: net income is positive (CNY 19.8m), book value is CNY 800.5m, and cash covers ~67% of debt, so this reads as a leverage-quality concern rather than near-term solvency risk. Backlog is null, so order momentum and customer-capex direction cannot be tested and no MedTech capex-cycle flag is supportable. No peer multiple, share price, or debt maturity schedule is in the fact set, so the distressed range the distress rule requires can only be framed qualitatively here, and the refinancing-within-12-months escalation trigger is unverifiable. Filings: no EDGAR ingestion (empty summaries); six SSE announcements are queued, including the 2025 audit report and 2025 dividend plan, so the fact set may lag reported results.

Full timeline · 31 filings · 0 with a parsed narrative

No qualitative filing summaries are parsed for this market yet — the timeline below lists the filings on record, but the narrative fields are US/HK-only for now.

OTHER2026-09-16
Source ↗
No parsed narrative for this filing.
OTHER2026-08-24
Source ↗
No parsed narrative for this filing.
OTHER2026-08-24
Source ↗
No parsed narrative for this filing.
OTHER2026-08-24
Source ↗
No parsed narrative for this filing.
OTHER2026-08-24
Source ↗
No parsed narrative for this filing.
OTHER2026-08-24
Source ↗
No parsed narrative for this filing.
OTHER2026-06-24
Source ↗
No parsed narrative for this filing.
OTHER2026-06-23
Source ↗
No parsed narrative for this filing.
OTHER2026-06-23
Source ↗
No parsed narrative for this filing.
OTHER2026-06-22
Source ↗
No parsed narrative for this filing.
OTHER2026-06-22
Source ↗
No parsed narrative for this filing.
OTHER2026-05-18
Source ↗
No parsed narrative for this filing.
OTHER2026-05-15
Source ↗
No parsed narrative for this filing.
OTHER2026-05-15
Source ↗
No parsed narrative for this filing.
OTHER2026-04-28
Source ↗
No parsed narrative for this filing.
OTHER2026-04-28
Source ↗
No parsed narrative for this filing.
OTHER2026-04-27
Source ↗
No parsed narrative for this filing.
OTHER2026-04-20
Source ↗
No parsed narrative for this filing.
OTHER2026-04-20
Source ↗
No parsed narrative for this filing.
OTHER2026-04-20
Source ↗
No parsed narrative for this filing.
OTHER2026-04-20
Source ↗
No parsed narrative for this filing.
OTHER2026-04-20
Source ↗
No parsed narrative for this filing.
OTHER2026-04-20
Source ↗
No parsed narrative for this filing.
OTHER2026-04-20
Source ↗
No parsed narrative for this filing.
OTHER2026-04-20
Source ↗
No parsed narrative for this filing.
OTHER2026-04-20
Source ↗
No parsed narrative for this filing.
OTHER2026-04-20
Source ↗
No parsed narrative for this filing.
OTHER2026-04-20
Source ↗
No parsed narrative for this filing.
OTHER2026-04-20
Source ↗
No parsed narrative for this filing.
OTHER2026-04-20
Source ↗
No parsed narrative for this filing.
OTHER2026-04-20
Source ↗
No parsed narrative for this filing.

Extracted facts only — this page reproduces the stored filing summaries; it computes no valuation. Not investment advice.